Johan Lindberg

Karolinska Institutet

Key publications

ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: A report from the ESMO Precision Medicine Working Group

Increased Pathway Complexity Is a Prognostic Biomarker in Metastatic Castration-Resistant Prostate Cancer.

Androgen Receptor Burden and Poor Response to Abiraterone or Enzalutamide in TP53 Wild-Type Metastatic Castration-Resistant Prostate Cancer.

TP53 Outperforms Other Androgen Receptor Biomarkers to Predict Abiraterone or Enzalutamide Outcome in Metastatic Castration-Resistant Prostate Cancer.

Cell-free DNA profiling of metastatic prostate cancer reveals microsatellite instability, structural rearrangements and clonal hematopoiesis.

The goal of my research is to enable personalized medicine for cancer patients. This can be achieved through biomarker-driven randomized clinical trials. Therefore, I have established a sample- and analysis procedure capable of performing prospective broad genomic profiling in a clinically relevant time frame. The procedure makes use of available infrastructures at KI/SciLife Lab and encompass reception and storage of biomaterial, subsequent processing for Illumina sequencing and analysis using an in-house developed bioinformatics pipeline and curation software.

Over the years my team has prospectively analyzed >5000 samples from a network of ~60 hospitals in six European countries. This includes projects such as:

ALASCCA – Adjuvant Låg dos ASA vid Colorektal Cancer
ALASCCA is a Nordic randomized clinical trial investigating the effect of adjuvant aspirin treatment of PI3K mutated localized colorectal cancer. The primary objective and endpoint will be analyzed during 2024.

ProBio – Prostate Biomarkers
ProBio is an adaptive, biomarker driven randomized randomized clinical trial addressing the unmet need for treatment predictive biomarkers in advanced prostate cancer. ProBio is currently including patients from nation-wide networks of hospitals in Sweden, Belgium, Norway and Switzerland.

iPCM – implementation of Personalized Cancer Medicine
The goal of the iPCM project is to transfer an existing research setup, enabling broad genomic profiling of cancer, into clinical routine and to simultaneously address unsolved research questions. The iPCM project is done in close collaboration with Felix Haglund (clinical pathology, onkpat), Päivi Östling (SciLife, onkpat), David Tamborero/Janne Lehtiö (SciLife, onkpat).

PSFF – Pre-screening for phase I clinical trials
PSFF is a pilot project with the goal to establish a routine molecular screening program for patients with advanced cancer at the Center for Clinical Cancer Studies at Karolinska Hospital.

These prospective sample collections are a rich resource for retrospective biomarker research.


Last updated: 2023-02-22

Content Responsible: Johan Inganni(